“This gives us a clear view of how the virus is evolving, which is important to know as we develop vaccines and therapies,” said TSRI biologist Kristian G. Andersen, a lead author of the new study.
At least 5,000 people die each year from Lassa fever. The virus is spread through contact with urine and droppings from infected Mastomys natalensis rodents (which are a natural “reservoir” of the virus)—and the disease can spread from human to human.
In the new study, published August 13 in the journal Cell, the team—whose senior members included Pardis Sabeti and Joshua Levin of Harvard University and the Broad Institute, Robert F. Garry of Tulane University and Christian Happi of Nigeria’s Irrua Specialist Teaching Hospital and Sierra Leone’s Kenema Government Hospital—used a technique called next-generation sequencing to analyze genomes of Lassa virus samples taken from wild Mastomys natalensis and human patients in Nigeria and Sierra Leone.
The genomic data showed that far-flung strains of Lassa virus share a common ancestor that can be traced back more than 1,000 years to an area today known as Nigeria. This surprised the researchers, as Lassa fever was first described in Nigeria in 1969. “The virus has very ancient roots,” said Andersen.
The researchers found that the virus spread out of Nigeria about 400 years ago and over the past couple of hundred years moved into Guinea, Liberia and Sierra Leone—the same part of the world where the largest outbreak of Ebola virus has been raging since 2013. As Lassa virus spread, the virus mutated and seemed to better adapt to mammalian hosts.
The new data also show that most Lassa fever cases are caused by frequent “spillover” infections from the wild rodent reservoir to humans, rather than spreading from human to human. “The reason Lassa hasn’t yet grown into this huge epidemic is because there is limited transmission between humans,” said Andersen. “That’s a major difference between Lassa virus and Ebola virus.”
Andersen noted that local scientists in West Africa were key for this new study and will be crucial for future studies in the region. He views the next step in this research as understanding how the virus mutates within individual hosts as it confronts the immune system.
In addition to Andersen, co-first authors of the study, “Clinical sequencing uncovers origins and evolution of Lassa virus,” were B. Jesse Shapiro of Harvard University, the Broad Institute and the University of Montréal and Christian B. Matranga of the Broad Institute. Other institutions represented included the Massachusetts Institute of Technology, Redeemer’s University in Nigeria, Zalgen Labs, Stanford University, Harvard School of Public Health, Columbia University, Nigeria Federal Ministry of Health, National Aeronautics and Space Administration, University of Texas School of Public Health, Bernhard-Nocht-Institute for Tropical Medicine, Viral Hemorrhagic Fever Consortium and the National Institute of Allergy and Infectious Diseases (NIAID) Integrated Research Facility. For a full listing of the authors, see the study at www.cell.com.
This research was supported by the National Institutes of Health (NIH) Department of Health and Human Services (1DP2OD006514-01), NIAID (BAA–NAID-DAIT-NIHAI2008031, BAA-NIAID-DAIT648, NIHAI2009061 and HHSN272200900018C), a Packard Foundation Fellowship for Science and Engineering, a Broad Institute SPARC award, a grant GU 883/1-1 from the German Research Foundation, a fellowship from the Carlsberg Foundation, a Harvard MIDAS CCDD postdoctoral fellowship and the Canada Research Chair program, and by National Science Foundation GRFP fellowships (DGE 1122374 and 1144152).
About The Scripps Research Institute
The Scripps Research Institute (TSRI) is one of the world’s largest independent, not-for-profit organizations focusing on research in the biomedical sciences. TSRI is internationally recognized for its contributions to science and health, including its role in laying the foundation for new treatments for cancer, rheumatoid arthritis, hemophilia, and other diseases. An institution that evolved from the Scripps Metabolic Clinic founded by philanthropist Ellen Browning Scripps in 1924, the institute now employs about 2,700 people on its campuses in La Jolla, CA, and Jupiter, FL, where its renowned scientists—including two Nobel laureates—work toward their next discoveries. The institute’s graduate program, which awards PhD degrees in biology and chemistry, ranks among the top ten of its kind in the nation. For more information, see www.scripps.edu.
# # #
Office of Communications